MedTrace Logo

BI 655066/ABBV-066 (Risankizumab) Compared to Active Comparator (Adalimumab) in Patients With Moderate to Severe Chronic Plaque Psoriasis

NCT02694523 · Status: COMPLETED · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 684

Last updated 2021-07-30

Study results available
· View outcomes & findings →

Summary

This is a randomized double blind, double dummy, active comparator controlled, parallel design study that is performed to assess the safety and efficacy of BI 655066/ABBV-066 (risankizumab) compared to adalimumab to support registration for the treatment of moderate to severe chronic plaque psoriasis in adult patients.

Conditions

Interventions

DRUG

risankizumab

Risankizumab administered by subcutaneous (SC) injection

BIOLOGICAL

adalimumab

Adalimumab pre-filled syringe, administered by subcutaneous (SC) injection

DRUG

placebo for risankizumab

Placebo risankizumab administered by subcutaneous (SC) injection

BIOLOGICAL

placebo for adalimumab

Placebo for adalimumab pre-filled syringe, administered by subcutaneous (SC) injection

Sponsors & Collaborators

Principal Investigators

  • Boehringer Ingelheim · Boehringer Ingelheim

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-03-31
Primary Completion
2017-08-31
Completion
2017-08-31

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02694523 on ClinicalTrials.gov